Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 16/20 | 0.52 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2288791 | 1.00 | CACNA2D1 (0.52) | CACNA2D1CACNA2D2SLC6A2LMNAPOLB | |
| SCHEMBL2292026 | 0.93 | CACNA2D1 (0.51) | CACNA2D1CACNA2D2SLC6A2KDR | |
| SCHEMBL2292019 | 0.93 | CACNA2D1 (0.51) | CACNA2D1CACNA2D2SLC6A2KDR | |
| SCHEMBL2289702 | 0.90 | CACNA2D1 (0.51) | CACNA2D1CACNA2D2SLC6A2LMNAPOLB | |
| SCHEMBL2289695 | 0.90 | CACNA2D1 (0.51) | CACNA2D1CACNA2D2SLC6A2LMNAPOLB | |
| SCHEMBL2288520 | 0.88 | CACNA2D1 (0.47) | CACNA2D1CACNA2D2SLC6A2F10KDR | |
| SCHEMBL2288513 | 0.88 | CACNA2D1 (0.47) | CACNA2D1CACNA2D2SLC6A2F10KDR | |
| SCHEMBL2288995 | 0.87 | CACNA2D1 (0.52) | CACNA2D1CACNA2D2SLC6A2 | |
| SCHEMBL2288362 | 0.87 | CACNA2D1 (0.52) | CACNA2D1CACNA2D2SLC6A2 | |
| SCHEMBL2289725 | 0.87 | CACNA2D1 (0.48) | CACNA2D1CACNA2D2SLC6A2F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2163554-B1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2163554-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KCNJ1, KCNJ11, ADRA1D | CACNA2D1 624/4885CACNA2D2 794/4885SLC6A2 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.